Last reviewed · How we verify
Paclitaxel dosing according to SmPC
Paclitaxel dosing according to SmPC is a Taxane Small molecule drug developed by Central European Society for Anticancer Drug Research. It is currently in Phase 3 development for Adjuvant treatment of node-positive breast cancer, Adjuvant treatment of completely resected non-small cell lung cancer, Treatment of ovarian cancer.
Paclitaxel works by inhibiting cell division, thereby preventing cancer cells from multiplying.
Paclitaxel works by inhibiting cell division, thereby preventing cancer cells from multiplying. Used for Adjuvant treatment of node-positive breast cancer, Adjuvant treatment of completely resected non-small cell lung cancer, Treatment of ovarian cancer.
At a glance
| Generic name | Paclitaxel dosing according to SmPC |
|---|---|
| Sponsor | Central European Society for Anticancer Drug Research |
| Drug class | Taxane |
| Target | Microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Paclitaxel binds to tubulin, stabilizing microtubules and preventing their disassembly. This prevents the formation of the mitotic spindle, a structure essential for cell division. As a result, cancer cells are unable to divide and multiply, leading to cell death.
Approved indications
- Adjuvant treatment of node-positive breast cancer
- Adjuvant treatment of completely resected non-small cell lung cancer
- Treatment of ovarian cancer
- Treatment of pancreatic cancer
- Treatment of AIDS-related Kaposi's sarcoma
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Fatigue
- Mucositis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paclitaxel dosing according to SmPC CI brief — competitive landscape report
- Paclitaxel dosing according to SmPC updates RSS · CI watch RSS
- Central European Society for Anticancer Drug Research portfolio CI
Frequently asked questions about Paclitaxel dosing according to SmPC
What is Paclitaxel dosing according to SmPC?
How does Paclitaxel dosing according to SmPC work?
What is Paclitaxel dosing according to SmPC used for?
Who makes Paclitaxel dosing according to SmPC?
What drug class is Paclitaxel dosing according to SmPC in?
What development phase is Paclitaxel dosing according to SmPC in?
What are the side effects of Paclitaxel dosing according to SmPC?
What does Paclitaxel dosing according to SmPC target?
Related
- Drug class: All Taxane drugs
- Target: All drugs targeting Microtubules
- Manufacturer: Central European Society for Anticancer Drug Research — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Adjuvant treatment of node-positive breast cancer
- Indication: Drugs for Adjuvant treatment of completely resected non-small cell lung cancer
- Indication: Drugs for Treatment of ovarian cancer